Agenus (NASDAQ:AGEN) Cut to Hold at Wall Street Zen

Agenus (NASDAQ:AGEN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Several other analysts have also commented on the company. B. Riley reiterated a “buy” rating on shares of Agenus in a report on Monday, April 21st. Robert W. Baird increased their price objective on Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a report on Wednesday, June 4th. HC Wainwright upgraded Agenus from a “neutral” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Wednesday, June 4th. Finally, Zacks Research upgraded Agenus to a “hold” rating in a report on Tuesday, August 12th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Agenus currently has a consensus rating of “Hold” and a consensus target price of $15.50.

Agenus Stock Up 1.8%

Agenus stock opened at $4.63 on Friday. The business has a fifty day moving average of $5.36 and a two-hundred day moving average of $3.70. The firm has a market cap of $147.51 million, a P/E ratio of -0.65 and a beta of 1.62. Agenus has a twelve month low of $1.38 and a twelve month high of $7.34.

Agenus (NASDAQ:AGEN) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.22). The business had revenue of $25.70 million during the quarter, compared to the consensus estimate of $49.71 million. Equities analysts expect that Agenus will post -12.55 earnings per share for the current year.

Hedge Funds Weigh In On Agenus

Several hedge funds have recently made changes to their positions in AGEN. B. Riley Financial Inc. acquired a new position in shares of Agenus in the 4th quarter valued at $2,074,000. Siren L.L.C. acquired a new position in shares of Agenus in the 1st quarter valued at $752,000. Marshall Wace LLP acquired a new position in shares of Agenus in the 2nd quarter valued at $1,976,000. AQR Capital Management LLC increased its position in shares of Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after acquiring an additional 427,604 shares during the period. Finally, Bank of America Corp DE grew its position in Agenus by 110.0% during the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after purchasing an additional 220,327 shares during the period. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.